Shanghai Henlius Biotech, Inc. (HKG: 2696)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
23.05
-0.10 (-0.43%)
Sep 9, 2024, 2:49 PM HKT
98.71%
Market Cap 12.55B
Revenue (ttm) 6.06B
Net Income (ttm) 743.92M
Shares Out 543.49M
EPS (ttm) 1.36
PE Ratio 16.93
Forward PE 19.15
Dividend n/a
Ex-Dividend Date n/a
Volume 321,100
Open 23.05
Previous Close 23.15
Day's Range 23.00 - 23.10
52-Week Range 9.60 - 23.45
Beta 0.81
Analysts n/a
Price Target n/a
Earnings Date Nov 15, 2024

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 3,637
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2696
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.